RxDoctor Payments Data

Lorrie Cooksey, APRN

Family · Savannah, TNNPI 1174680755

Payments from drug & device makers

$2,548in general payments, 2019–2025

Across 169 payments — averaging $15.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$570
  • Lilly USA, LLC$333
  • Boehringer Ingelheim$105
  • Pfizer$75
  • Biohaven Pharmaceuticals, Inc.$70
  • plus $207 from 7 others

What the payments were for

  • Food & beverage$2,50398%
  • Education$452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,548 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$54,853
Medicare patients
125
Services billed
4,053

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide116$129,708
MounjaroTirzepatide107$122,930
LinzessLinaclotide58$42,825
EliquisApixaban47$36,906
JardianceEmpagliflozin49$29,504
Repatha SureclickEvolocumab38$29,397
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$26,384
VraylarCariprazine Hcl18$26,275
FarxigaDapagliflozin Propanediol24$21,816
Nurtec OdtRimegepant Sulfate19$17,905
XareltoRivaroxaban19$17,499
QuliptaAtogepant11$12,087
Janumet XrSitagliptin Phos/Metformin Hcl17$11,924
TrintellixVortioxetine Hydrobromide16$11,880
Ondansetron Hcl47$8,860

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,189$129,708116 claims
Lilly USA, LLCMounjaro$333$122,930107 claims
AbbVieLinzess, Vraylar, Qulipta$570$81,18787 claims
PfizerEliquis, Nurtec Odt$75$54,81166 claims
Boehringer IngelheimJardiance$105$29,50449 claims
AstraZenecaFarxiga, Symbicort$31$24,54336 claims
MerckJanumet Xr$11$11,92417 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$48$11,88016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,706 family providers in Tennessee.

Other family in Savannah

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →